Automated Immunoassay Analyzers Market - By Product (Immunofluorescence, Chemiluminescence, ELISA), By Application (Infectious Diseases, Endocrinology, Allergy Testing), By End-use (Hospitals, Diagnostic Laboratories), & Forecast, 2023 – 2032

Automated Immunoassay Analyzers Market - By Product (Immunofluorescence, Chemiluminescence, ELISA), By Application (Infectious Diseases, Endocrinology, Allergy Testing), By End-use (Hospitals, Diagnostic Laboratories), & Forecast, 2023 – 2032

Automated Immunoassay Analyzers Market Size

Automated Immunoassay Analyzers Market size crossed USD 16.9 billion in 2022 and is slated to depict around 14.3% CAGR from 2023 to 2032.

Recent trends related to automation and integration of advanced technologies has led to introduction of innovative products in the market. Numerous biotechnology and pharmaceutical companies are increasingly using such products for drug discovery, allergy testing, among various other purposes. Increasing prevalence of infectious diseases, novel product launches, growing range of clinical applications of immunoassay analyzers are other variables that are anticipated to propel the product adoption rate. In addition, such aforementioned factors are set to cumulatively drive the automated immunoassay analyzers industry growth.

An immunoassay analyzer is an advanced tool used in hospitals and laboratories to automate the process of analyzing immunoassays and run biochemical tests to detect the presence and concentration of substances in the given samples. It is a compact, easy to use machine that delivers fast and reliable results.

The automated immunoassay analyzers market is likely to impede tremendous growth due to dearth of qualified and trained professionals in healthcare sector. With the growing elderly population across the world, there is an increasing need for qualified professionals in healthcare facilities such as hospitals, diagnostics, and reference laboratories. Thus, lack of well-trained professionals to maintain the minimum standards of healthcare is predicted to hamper the industry growth.

COVID-19 Impact

The recent outbreak of COVID-19 pandemic had a negative impact on the automated immunoassay analyzers market revenue in 2020. Several restrictions including nation-wide lockdowns were imposed across different countries globally to avoid the spread of the virus. The COVID-19 outbreak had affected the overall healthcare industry including immunoassay analyzers market. Numerous factors including interruption of non-emergent medical services, equipment demand and supply shortages, supply chain disturbances, among other disruptions impacted the market revenue.
 

As the COVID-19 infection rate decreased the industry witnessed a rapid recovery and an incremental surge in the year-on-year growth trend in the following years. However, the decline in number of patients, propelled the product adoption rate and contributed positively to the market growth.

Automated Immunoassay Analyzers Market Trends

Increasing prevalence of infectious diseases is one of the pivotal factors that is set to drive automated immunoassay analyzers market growth. Early detection of infectious diseases is important to reduce the possibility of severe damage to the body. Thus, accurate and precise screening of infections such as Hepatitis, influenza, STDs, and numerous other infections in minimal time is projected to be a major market growth factor. Furthermore, awareness of diseases has increased the disease diagnosis in early stages for preventing complications by undergoing diagnostic tests.

Automated Immunoassay Analyzers Market Analysis

The chemiluminescence immunoassay analyzer segment of automated immunoassay analyzers market exceeded USD 5.3 billion in 2022. The largest share is attributed to increasing use owing to high accuracy and sensitivity of the diagnosis using low analyte concentration. These immunoassay analyzers improve the work competence by identification of more than hundreds of analytes per hour. The higher receptiveness and reliability of chemiluminescence immunoassay will drive customer preference for these products. Thus, the above-mentioned parameters are likely to boost the segmental progression.
 

Based on application, the infectious diseases segment dominated the automated immunoassay analyzers market in terms of revenue and was valued at USD 5.0 billion in 2022. Infectious diseases are caused by pathogenic microorganisms such as parasites, bacteria and viruses and are highly communicable. Intensifying adoption of advanced molecular techniques coupled with increasing government and non-profit organization’s intervention aiming to reduce the burden of infectious diseases especially in underdeveloped and developing regions will drive the industry growth.
 

The hospitals segment is anticipated to witness 14.7% CAGR through 2032. Rise in target population of people suffering from heart and lungs related disorders, increasing awareness level, facilitative reimbursement schemes and availability of better care facilities among others are prime factors responsible for increasing patient footfall in hospital settings. Additionally, presence of well-trained and equipped healthcare personnel, availability of better infrastructure and advanced equipment for improved diagnostic testing such as cardiac marker testing, along with supportive government schemes focusing on reducing the heart related disease burden will further fuel the segmental growth. Moreover, owing to afore-mentioned pointers, the market is observing robust growth.
 

North America automated immunoassay analyzers market and is expected to reach over USD 23.2 billion by 2032. Increasing prevalence of infectious diseases, different allergies, and cancer will contribute to the rising demand for automated immunoassay analyzers for accurate and early diagnosis across North America over the forecast period. Favorable demographic trends including presence of significant patient pool, rise in geriatric population, increasing awareness and average life expectancy will render significant positive impact.

Automated Immunoassay Analyzers Market Share

Few of the leading players operating in the automated immunoassay analyzers market include

• F. Hoffmann-La Roche AG
• Abbott Laboratories
• BioMerieux
• BioRad Laboratories
• Perkin Elmer
• Biokit
• Luminex Corporation

 The market is consolidated in nature, with leading players, regional and local companies, along with start-ups further consolidating the industry competition. The leading market players are involved in strategic developments including research and development, novel product launches, partnerships, to improve their market positioning and revenue generating capabilities.

Automated Immunoassay Analyzers Industry News

• In November 2021, Boditech Med, based in Korea, launched its New Automated Immunoassay Analyzer with Blood Collection Tube. It comes with unique capability of executing 10 parallel tests for each different parameter. This strategic development to boost the company's revenue and its industry presence in the coming years.

   

• In September 2021, Thermo Fisher Scientific has launched its fully-automated analyzers specifically designed for enzyme assay applications. The new analyzers systems combine hardware and new custom-designed software to provide fully automated incubation settings, precise measurement calculations and reagent additions. This development is playing a key role in expanding company's product portfolio and business growth.
   

This automated immunoassay analyzers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in (USD million) and volume (Units) from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Product

• Immunofluorescence
• Chemiluminescence
• ELISA (enzyme-linked immunosorbent assay)
• Enzyme linked fluorescent system
• Multiplexed assay system
• Radioimmunoassay

By Application

• Infectious disease
  • Influenza
  • HIV
  • Hepatitis C
  • Sexually Transmitted Disease (STD)
  • Healthcare-Associated Infection (HAI)
  • Respiratory infection
  • Tropical disease
  • Others
• Endocrinology
• Drug Monitoring
• Cardiology
• Oncology
• Allergy Testing
• Others

By End-use

• Hospitals
• Diagnostic Laboratories
• Research and Academic Laboratories
• Pharmaceutical and Biotechnology Companies
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Peru
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Israel
  • Iran